Aspen has identified four priorities for the firm as it seeks to transform from a regional generics business to a global specialty company. The group said its shift in focus was “vindicated by changes in the pharmaceutical industry, particularly pricing pressure in generics”.
Aspen Outlines Four Priorities As Focus Shifts To Global Specialty
Disposing of its Nutritionals business allows Aspen to fully focus on pharmaceuticals, while the firm is looking to drive organic growth with an emphasis on its Emerging Markets division, optimizing its complex manufacturing capabilities and seeking collaborations in territories where it “lacks sufficient critical mass”. These are among the measures Aspen has identified as it outlines four priorities for the firm, as the group shifts from being a regional generics company to a global specialty business.
More from Earnings
More from Business
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.